

This method enables the detection of heparin contamination with other sulfated glycans, in particular in the case of inadmissible heparin imitations such as oversulfated chondroitin sulfate, as well as of high amounts of other glycosaminoglycans and proteins. In 2008, heparin contaminated with oversulfated chondroitin sulfate penetrated the worldwide market and was associated with severe adverse effects. This is a simple and reliable method to test heparin for adulteration, thus improving pharmaceutical quality control.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner